Business
Hyphens Pharma out‑licences Cerapro® MED Skin Barrier Cream for six European countries
Hyphens Pharma International Limited ("Hyphens Pharma", or the "Company", and together with its subsidiaries, the "Group"), Singapore's leading specialty pharmaceutical and consumer healthcare group, is pleased to announce that it has granted the rights to commercialise its innovative product, Cerapro® MED Skin Barrier Cream, to Louis Widmer SA ("Louis Widmer") via a licensing, supply and commercialisation agreement ("Out-Licensing Agreement") that covers six European countries, namely Switzerla
About this update from Hyphens Pharma International Ltd.
[{"type":"list","items":[{"val":[{"type":"text","content":"Cerapro® is a patented, skin pH-lowering cream approved for the treatment of atopic dermatitis under the European Medical Device Regulation (CE Mark)","length":149,"tagName":"p"}]},{"val":[{"type":"text","content":"Product launch targeted for 2026 in six European markets, including Switzerland, Austria, the Netherlands and Belgium. ","length":118,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":267,"olType":false},{"type":"text","content":"SINGAPORE, Jan. 5, 2026 /PRNewswire/ -- Hyphens Pharma International Limited ("Hyphens Pharma", or the "Company", and together with its subsidiaries, the "Group"), Singapore's leading specialty pharmaceutical and consumer healthcare group, is pleased to announce that it has granted the rights to commercialise its innovative product, Cerapro® MED Skin Barrier Cream, to Louis Widmer SA ("Louis Widmer") via a licensing, supply and commercialisation agreement ("Out-Licensing Agreement") that covers six European countries, namely Switzerland, Liechtenstein, Austria, Belgium, Luxembourg and the Netherlands.","length":667,"tagName":"p"},{"type":"text","content":"In accordance with the Out-Licensing Agreement with Louis Widmer, Hyphens Pharma will receive an upfront fee and customary royalties on sales.","length":142,"tagName":"p"},{"type":"text","content":"Atopic dermatitis, a common form of eczema, affects millions across all age groups. Elevated skin pH and impaired skin barrier function are key drivers of this skin condition. Cerapro®, with its patented formulation, lowers skin pH and helps restore the skin barrier. Approved as a CE-marked medical device under the stringent European Medical Device Regulation (MDR), Cerapro® offers a novel treatment option for patients with eczema. Lowering skin pH also supports the skin's inherent antimicrobial defence system.","length":520,"tagName":"p"},{"type":"text","content":"Under this collaboration, Louis Widmer, a Swiss-based international cosmetics and pharmaceuticals company renowned for high-quality dermatology products since 1960, will commercialise and promote Cerapro® to dermatologists and paediatricians in the agreed markets. This collaboration reflects the shared vision of both companies to deliver science-backed products that enhance patient...